Further MT for AntIbiotic-Resistant Bacterial Colonization in Inpatients
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to better understand the effectiveness and safety of microbiome
therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO)
colonization after an infection. Limited data from prior studies suggest that MT may be an
effective treatment to reduce intestinal MDRO colonization Although shedding of MDROs from
patients to their surrounding environment is a recognized pathway of transmission, the
potential effect of MT on the transmission of MDRO to other patients in the hospital
environment is unclear. This study will test the safety and efficacy of MT for this use in
hospitalized patients. This study will also help design larger studies.
The MT may help reduce MDROs that colonize the gut. By reducing colonization before
infections happen, this could help doctors avoid using "last resort" antibiotics that can
have serious side effects like kidney damage. The reduction in MDROs after MT was originally
identified in patients treated with MT for recurrent Clostridioides difficile (often called
"C. diff") diarrhea. It has been shown that a type of MT called fecal microbiota transplant
(FMT) can eliminate both C. difficile and other resistant bacteria.